27 related articles for article (PubMed ID: 15685828)
1. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.
Chen G; Huynh M; Fehrenbacher L; West H; Lara PN; Yavorkovsky LL; Russin M; Goldstein D; Gandara D; Lau D
J Clin Oncol; 2009 Mar; 27(9):1401-4. PubMed ID: 19204194
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan and carboplatin in metastatic or recurrent non-small-cell lung cancer.
Govindan R; Read W; Faust J; Mc Leod H
Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):27-9. PubMed ID: 12886871
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC.
Natale RB; Socinski M; Sandler A; Israel VP; Miller L
Oncology (Williston Park); 2000 Jul; 14(7 Suppl 5):29-34. PubMed ID: 10981288
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.
Socinski MA; Sandler AB; Miller LL; Locker PK; Hanover CK; Elfring GL; Israel VK; Pirotta N; Natale RB
J Clin Oncol; 2001 Feb; 19(4):1078-87. PubMed ID: 11181672
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report.
Pillot GA; Read WL; Hennenfent KL; Marsh S; Gao F; Viswanathan A; Cummings K; McLeod HL; Govindan R
J Thorac Oncol; 2006 Nov; 1(9):972-8. PubMed ID: 17409981
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan and carboplatin in metastatic or recurrent NSCLC: an update.
Read W; McLeod H; Govindan R
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):15-7. PubMed ID: 15685828
[TBL] [Abstract][Full Text] [Related]
8. Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
Jones SF; Burris HA; Hainsworth JD; Yardley DA; Raefsky EA; Miranda FT; Kuzur ME; Willcutt NT; White MB; Greco FA
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):36-40. PubMed ID: 12800605
[TBL] [Abstract][Full Text] [Related]
9. The emerging world role of irinotecan in lung cancer.
Langer CJ
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):15-21. PubMed ID: 11497227
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
Okamoto I; Moriyama E; Fujii S; Kishi H; Nomura M; Goto E; Kiyofuji C; Imamura F; Mori T; Matsumoto M
Jpn J Clin Oncol; 2005 Apr; 35(4):188-94. PubMed ID: 15845567
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer.
Natale RB
Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):22-6. PubMed ID: 12886870
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pharmacogenetic factors associated with irinotecan toxicity.
Kweekel D; Guchelaar HJ; Gelderblom H
Cancer Treat Rev; 2008 Nov; 34(7):656-69. PubMed ID: 18558463
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
